Arun K Rishi
Overview
Explore the profile of Arun K Rishi including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
77
Citations
1776
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
21.
Dai X, Thiagarajan D, Fang J, Shen J, Annam N, Yang Z, et al.
PLoS One
. 2017 Dec;
12(12):e0190191.
PMID: 29284006
Vascular smooth muscle cell (VSMC) phenotypic modulation is characterized by the downregulation of SMC actin cytoskeleton proteins. Our published study shows that depletion of SM22α (aka SM22, Transgelin, an actin...
22.
Yin S, Cheryan V, Xu L, Rishi A, Reddy K
PLoS One
. 2017 Aug;
12(8):e0183578.
PMID: 28817737
Women with triple negative breast cancer (TNBC) have poor prognosis compared to other breast cancer subtypes. There were several reports indicating racial disparity in breast cancer outcomes between African American...
23.
Ashour A, Badran M, Kumar A, Rishi A, Yassin A
IEEE Trans Nanobioscience
. 2016 Dec;
15(7):739-747.
PMID: 28029617
In the current study, 5-FU-loaded nanoparticles (NPs) were prepared using polylactic-co-glycolic acid (PLGA), polycaprolactone (PCL), di-block poly lactide-co-caprolactone (PLCL) and tri-block poly L-lactide-co-caprolactone-co-glycolide (PLCLG). The influence of these polymers on...
24.
Cheriyan V, Muthu M, Patel K, Sekhar S, Rajeswaran W, Larsen S, et al.
Oncotarget
. 2016 Oct;
7(45):73370-73388.
PMID: 27687593
Doxorubicin and Cisplatin are the frontline therapeutics for treatment of the triple negative breast cancers (TNBCs). Emergence of drug-resistance often contributes to failure of drugs and poor prognosis, and thus...
25.
Luong D, Kesharwani P, Killinger B, Moszczynska A, Sarkar F, Padhye S, et al.
J Colloid Interface Sci
. 2016 Sep;
484:33-43.
PMID: 27585998
Conventional chemotherapy using small molecule drugs is marred by several challenges such as short half-life, low therapeutic index and adverse systemic side effects. In this regard, targeted therapies using ligand...
26.
Ashour A, Ahmed A, Kumar A, Zoheir K, Aboul-Soud M, Ahmad S, et al.
Mol Cell Biochem
. 2016 Apr;
416(1-2):141-55.
PMID: 27084536
Medulloblastoma (MB) is the most common malignant brain tumor of childhood. The transcription factor NF-κB is overexpressed in human MB and is a critical factor for MB tumor growth. NF-κB...
27.
Andey T, Patel A, Marepally S, Chougule M, Spencer S, Rishi A, et al.
PLoS One
. 2016 Jan;
11(1):e0146804.
PMID: 26757437
Purpose: To formulate hydroxypropyl methylcellulose-stabilized self-emulsifying solid dispersible carriers of noscapine to enhance oral bioavailability. Methods: Formulation of noscapine (Nos) self-emulsifying solid dispersible microparticles (SESDs) was afforded by emulsification using...
28.
Muthu M, Somagoni J, Cheriyan V, Munie S, Levi E, Ashour A, et al.
J Biomed Nanotechnol
. 2015 Oct;
11(9):1608-27.
PMID: 26485930
The triple negative breast cancer (TNBCs) and non-small cell lung cancers (NSCLCs) often acquire mutations that contribute to failure of drugs in clinic and poor prognosis, thus presenting an urgent...
29.
Chukkapalli S, Levi E, Rishi A, Datta N
Endocrine
. 2015 Aug;
51(3):534-44.
PMID: 26260694
The effectiveness of chemotherapeutic agents often limits their use due to their negative effects on normal cells. Apoptosis regulatory protein (CARP)-1 functional mimetics (CFMs) belong to a novel class of...
30.
Muthu M, Cheriyan V, Rishi A
Oncotarget
. 2015 Apr;
6(9):6499-510.
PMID: 25894788
Targeted cancer therapy using small molecule inhibitors (SMIs) has been useful in targeting the tumor cells while sparing the normal cells. Despite clinical success of many targeted therapies, their off-target...